Annett Hessel, PhD obtained her MS in Biology from Faculty of Biosciences, Pharmacy and Psychology, at the University Leipzig in Germany (2006). Afterwards, she joined the Molecular Vaccines/Virology R&D group at Baxter and graduated with a PhD in Medical Science from the Medical University Vienna / Baxter (2011). Annett’s PhD studies involved the isolation of influenza genes and cloning into poxviruses and using recombinant viruses studied the humoral and cellular immune response based on different influenza proteins in mouse model. Annett continued to work at the Baxter Orth Molecular Vaccines group, where her work focused on recombinant Poxviruses, Influenza viruses and Flaviviruses. In 2014, Pfizer acquired the vaccine business from Baxter and Annett joined the Vaccines Analytical Development (MSAT) group where she was responsible for recombinant Flaviviruses, FSME small scale model development work, and development/improvement of various other bioassays (qPCR and ELISA). Since June 2017, Annett is leading the Vaccines Analytical Development group where she is responsible for a number of projects, e.g. development of an in vitro potency assay for FSME Immun®.